Compare UEIC & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UEIC | NSRX |
|---|---|---|
| Founded | 1986 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.3M | 53.5M |
| IPO Year | 1995 | N/A |
| Metric | UEIC | NSRX |
|---|---|---|
| Price | $3.76 | $4.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $9.25 | ★ $20.50 |
| AVG Volume (30 Days) | ★ 48.6K | 2.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.79 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $394,879,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.69 | $4.90 |
| 52 Week High | $7.90 | $9.99 |
| Indicator | UEIC | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.31 | 40.31 |
| Support Level | $3.68 | N/A |
| Resistance Level | $3.79 | $6.39 |
| Average True Range (ATR) | 0.17 | 0.73 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 5.08 | 10.78 |
Universal Electronics Inc is a United States-based company that principally designs, develops, manufactures, ships, and supports control and sensor technology solutions and a broad line of universal control systems, audio-video (AV) accessories, wireless security, and smart home products that are used by the world's brands in the video services, consumer electronics, security, home automation, climate control and home appliance markets. It generates its total revenue from the United States.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.